

## CLAIMS

1. A pharmaceutical composition comprising a compound comprising the tetrapeptide motif D/E-D/E-G/K-W, and a pharmaceutically acceptable carrier.  
5
2. The pharmaceutical composition according to claim 1, wherein the tetrapeptide motif is DDGW.
3. Use of a compound comprising the tetrapeptide motif D/E-D/E-G/K-W for the  
10 manufacture of a pharmaceutical composition for the treatment of conditions dependent on leukocyte migration.
4. Use according to claim 3 wherein the condition dependent on leukocyte migration is leukaemia.
- 15 5. Use according to claim 3 for the manufacture of a pharmaceutical composition for inhibiting the adhesion of progelatinases to  $\beta_2$ -integrins.
6. Use of the compound comprising the tetrapeptide motif D/E-D/E-G/K-W for the  
20 manufacture of a pharmaceutical composition for prophylaxis and treatment of conditions dependent on neutrophil migration.
7. Use according to claim 6 for the manufacture of a pharmaceutical composition for prophylaxis and treatment of inflammatory conditions.
- 25 8. Use according to any one of claims 3 to 7, wherein the tetrapeptide motif is DDGW.
9. A method for therapeutic or prophylactic treatment of conditions dependent on leukocyte migration, comprising administering to a mammal in need of such treatment a  
30 compound comprising the tetrapeptide motif D/E-D/E-G/K-W in an amount which is effective in inhibiting leukocyte migration.
10. A method for therapeutic or prophylactic treatment of conditions dependent on neutrophil migration, comprising administering to a mammal in need of such treatment

a compound comprising the tetrapeptide motif D/E-D/E-G/K-W in an amount which is effective in inhibiting neutrophil migration.

11. A method for therapeutic or prophylactic treatment of leukaemia, comprising  
5 administering to a mammal in need of such treatment a compound comprising the  
tetrapeptide motif D/E-D/E-G/K-W in an amount which is effective in inhibiting  
leukaemia cell migration.
12. A method for therapeutic or prophylactic treatment of inflammatory conditions,  
10 comprising administering to a mammal in need of such treatment a compound  
comprising the tetrapeptide motif D/E-D/E-G/K-W in an amount which is effective in  
inhibiting neutrophil migration.
13. The method according any one of claims 9 to 12, wherein the tetrapeptide motif is  
15 DDGW.